Linerixibat Reduces Itch in Primary Biliary Cholangitis

A systematic review and meta-analysis of three randomized controlled trials indicates that linerixibat provides a modest reduction in pruritus severity and sleep interference for adults with primary biliary cholangitis. The study, published in BMC Gastroenterology, evaluated the efficacy and safety of this ileal bile acid transporter inhibitor in patients whose itching was refractory to current therapies. The analysis combined data from 407 participants across trials of varying designs, including a phase 2a crossover study, a phase 2b dose-ranging study, and a phase 3 trial. The researchers found that while the medication improved specific itch metrics, it was associated with a higher frequency of gastrointestinal adverse events and treatment discontinuation.

Primary biliary cholangitis is an autoimmune cholestatic liver disease in which pruritus is a common and often refractory symptom. Current therapies have been described as poorly serving this specific clinical need, prompting the evaluation of linerixibat. The drug functions as an ileal bile acid transporter inhibitor, a mechanism that has been evaluated in randomized controlled trials for this condition. The systematic review followed the PRISMA 2020 guidelines and a prospectively registered PROSPERO protocol to assess the available evidence. Five databases were searched up to April 2026 to identify relevant studies comparing linerixibat with placebo in adults with PBC and cholestatic pruritus.

The primary outcome of the meta-analysis was the change from baseline in the Worst Itch Numerical Rating Scale, abbreviated as WI-NRS. Random-effects meta-analyses were conducted using the generic inverse-variance method to pool the results. The multi-arm trial contributed a single comparison to the analysis, while the crossover trial was entered using within-participant estimates. The certainty of the evidence was rated using the GRADE framework. The included trials had treatment durations of up to 24 weeks, providing data on short-to-medium-term efficacy and safety profiles.

The results showed that linerixibat reduced the WI-NRS score compared with placebo, with a mean difference of −0.95. The medication also reduced pruritus-related sleep interference, showing a mean difference of −0.68 with a 95% confidence interval from −1.23 to −0.13. However, the proportion of patients achieving a reduction of at least two points on the WI-NRS scale did not differ significantly between the linerixibat and placebo groups. The risk ratio for this outcome was 1.08, with a 95% confidence interval from 0.91 to 1.28, suggesting that while average scores improved, the likelihood of achieving a substantial individual response was not statistically distinct from placebo.

Biomarker analysis provided further insight into the drug’s mechanism of action. Serum C4 levels increased and FGF-19 levels decreased in the linerixibat group, findings that are consistent with the inhibition of the ileal bile acid transporter. Pooled differences in total bile acids and auto-taxin were not statistically significant. These biochemical changes support the pharmacological activity of the drug in the target population. The study did not report long-term efficacy or safety data, as the included trials were limited to durations of up to 24 weeks. The authors noted that long-term outcomes remain to be established in future research.

Safety data indicated that linerixibat was associated with more frequent adverse events compared with placebo. The risk ratio for any adverse event was 1.22, with a 95% confidence interval from 1.10 to 1.35. Diarrhea was significantly more common in the linerixibat group, with a risk ratio of 3.74 and a 95% confidence interval from 2.58 to 5.43. Abdominal pain also occurred more frequently, with a risk ratio of 3.84 and a 95% confidence interval from 1.83 to 8.08. Discontinuation due to adverse events was higher in the treatment group, with a risk ratio of 3.19 and a 95% confidence interval from 1.36 to 7.48.

The study authors concluded that linerixibat produces a modest reduction in pruritus severity and sleep interference in adults with primary biliary cholangitis. This benefit is accompanied by a higher incidence of gastrointestinal adverse events and treatment discontinuation.

Subject of Research: Efficacy and safety of linerixibat for refractory pruritus in primary biliary cholangitis

Article Title: Linerixibat for refractory pruritus in primary biliary cholangitis: a systematic review and meta-analysis

Article References: Al-Harbi, F. A., Aljabr, M. N., Alromayan, G. I., Aljarboa, N. A., Altasan, A. M., Alrashidi, F. K., Alharbi, F. M., AlMohaimeed, N. Y., Alreshoodi, A. T., Alzuhairy, A. A., Almansour, O., & Tesfaye, M. (2026). Linerixibat for refractory pruritus in primary biliary cholangitis: a systematic review and meta-analysis. BMC Gastroenterology. https://doi.org/10.1186/s12876-026-05479-w

Image Credits: AI Generated

DOI: 10.1186/s12876-026-05479-w

Keywords: linerixibat, primary biliary cholangitis, pruritus, meta-analysis, systematic review, IBAT inhibitor, gastroenterology, randomized controlled trials, cholestatic liver disease, adverse events, refractory, primary